Prions and blood products

References

• Kretzschmar HA. Neuropathology of human prion diseases (spongiform encephalopathies). Dev Biol Stand 1993; 80: 71–90
   Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95: 13363–83
   PubMed Web of Science ®Google Scholar
• Will R G, Ironside J W, Zeidler M, Cousens S N, Estiberio K, Alperovitch A. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921–5
   PubMed Web of Science ®Google Scholar
• Prusiner S B, Scott M R, DeArmond S J, Carlson G. Transmission and replication of prions. Prion biology and diseases, SB Prusiner. Cold Spring Harbor Laboratory Press, New York, NY 1999; 147–90
   Google Scholar
• Masters C L, Richardson EP. Subacute spongiform encephalopathy Creutzfeldt-Jakob disease — the nature and progression of spongiform change. Brain 1978; 101: 333–44
   PubMed Web of Science ®Google Scholar
• Kondo K, Kuroina Y. A case control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann Neurol 1981; 11: 377–81
   Google Scholar
• Will R G, Matthews WB. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1982; 45: 235–8
   PubMed Web of Science ®Google Scholar
• Davanipour Z, Goodman L, Alter M, Sobel E, Asher D, Gajdusek DC. Possible modes of transmission of Creutzfeldt-Jakob disease. N Engl J Med 1984; 311: 1582–3
   Google Scholar
• Bernoulli C, Siegfried J, Baumgartner G, Regli F, Rabinowicz T, Gajdusek D C. Danger of accidental person to person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1987; i: 478–9
   Google Scholar
• Duffy P, Wolf J, Collins G, DeVoe A G, Streeten B, Cowen D. Possible person to person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974; 290: 692–3
   PubMed Web of Science ®Google Scholar
• Otto D. Jacob-Creutzfeldt disease associated with cadaveric dura. J Neurosurg 1987; 67: 149
   Google Scholar
• Thadani V, Penar P L, Partington J, Kalb R, Janssen R, Schonberger L B. Creutzfeldt-Jakob disease probably acquired from a cadeveric dura mater graft. Case report. J Neurosurg 1988; 69: 766–9
   PubMed Web of Science ®Google Scholar
• Masullo C, Pocchiari M, Macchi G, Alema G, Piazza G, Panzera MA. Transmission of Creutzfeldt-Jakob disease by dural cadaveric graft. J Neurosurg 1989; 71: 954–5
   PubMed Web of Science ®Google Scholar
• Nisbet T J, MacDonaldson I, Bisbara SN. Creutzfeldt-Jakob disease in a second patient who received a cadaveric dura mater graft. JAMA 1989; 261: 1118
   Google Scholar
• Miyashita K, Inuzuka T, Kondo H, Saito Y, Fujita N, Matsubara N. Creutzfeldt-Jakob disease in a patient with a cadaveric dural graft. Neurology 1991; 41: 940–1
   Google Scholar
• Willison H J, Gale A N, McLaughlin JE. Creutzfeldt-Jakob disease following cadaveric dura mater graft. J Neurol Neurosurg Psychiatry 1991; 54: 940
   Google Scholar
• Brown P, Preece M A, Will RG. ‘Friendly fire’ in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992; 340: 24–7
   PubMed Web of Science ®Google Scholar
• Martinez-Lage J F, Sola J, Poza M, Esteban JA. Paediatric Creutzfeldt-Jakob disease: probable transmission by dural graft. Childs Nerve Syst 1993; 9: 239–42
   PubMed Web of Science ®Google Scholar
• Center for Disease Control. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts, Japan, January 1979-May 1996. Morb Mortal Wkly Rep 1997; 46: 1066–9
   Google Scholar
• Cochius J I, Burns R J, Blumbergs P C, Mack K, Alderman CP. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust N Z J Med 1990; 20: 592–3
   Google Scholar
• Cochius J I, Hyman N, Esiri MM. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin: a second case. J Neurol Neurosurg Psychiatry 1992; 55: 1094–5
   Web of Science ®Google Scholar
• Healy D L, Evans J. Creutzfeldt-Jakob disease after pituitary gonadotrophins. The prion is the problem. BMJ 1993; 307: 517–8
   PubMedGoogle Scholar
• Koch T K, Berg B O, DeArmond S J, Gravina RF. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. N Engl J Med 1985; 313: 731–3
   PubMed Web of Science ®Google Scholar
• Gibbs C J, Joy A, Heffner R, Franko M, Miyazaki M, Asher D M. Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. N Engl J Med 1985; 313: 734–8
   PubMed Web of Science ®Google Scholar
• Powell-Jackson J, Weller R O, Kennedy P, Preece M A, Whitcombe E M, Newsome-Davis J. Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet 1985; ii: 244–6
   Google Scholar
• Buchanan C R, Preece M A, Milner R DG. Mortality, neoplasia and Creutzfeldt-Jakob disease in patients treated with pituitary growth hormone in the United Kingdom. BMJ 1991; 302: 824–8
   PubMed Web of Science ®Google Scholar
• Fradkin J E, Schonberger L B, Mills J L, Gunn W J, Piper J M, Wysowski D K. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991; 265: 880–4
   PubMed Web of Science ®Google Scholar
• Billette de Villemeur T, Beauvais P, Gourmelen M, Richardet JM. Creutzfeldt-Jakob disease in children treated with growth hormone. Lancet 1991; 337: 864–5
   Google Scholar
• Billette de Villemeur T, Deslys J P, Pradel A, Soubrii C, Alpirovitch A, Tardieu M. Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology 1996; 47: 690–5
   Google Scholar
• Brown P. Environmental causes of human spongiform encephalopathy. Prion diseases, HF Baker, RM Ridley. Humana Press, Totowa, NJ 1996; 139–54
   Google Scholar
• Huillard d'Aignaux J, Costaglio D, Macciario J, Billette de Villemeur T, Brandel J P, Deslys J P. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999; 53: 1197–201
   Google Scholar
• Preece MA. Creutzfeldt-Jakob disease: implications for growth hormone deficient children. Neuropathol Appl Neurobiol 1986; 12: 509–15
   Google Scholar
• Food and Drug Administration. Deferral of donors who have received human pituitary-derived growth hormone. Memorandum from the Office of Biologics Research and Review; 1987 Nov 25. Office of Biologics, Bethesda, MD 1987
   Google Scholar
• Contreras M, Barbara J. Creutzfeldt-Jakob disease and blood transfusion. BMJ 1991; 302: 1148
   Google Scholar
• Watkins AM. Creutzfeldt-Jakob disease and blood transfusion. BMJ 1991; 302: 1537
   Google Scholar
• Esmonde T FG, Will R G, Slattery J M, Knight R, Harries-Jones R, DeSilva R. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993; 341: 205–7
   PubMed Web of Science ®Google Scholar
• Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case control studies. BMJ 2000; 321: 17–9
   PubMedGoogle Scholar
• Note for guidance. Guidelines for minimising the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnologyl Pharmacy and Working Party on Safety Medicines. Biologicals 1992; 20: 155–8
   Google Scholar
• World Health Organization. Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives (Requirements for Biological Substances No. 27, revised 1992). WHO Technical Report Series 1994; 840, Annex 2
   Google Scholar
• Council of Europe. Guide to the preparation, use and quality assurance of blood components. 2nd edn. Council of Europe Press, StrasbourgFrance 1995
   Google Scholar
• Food and Drug Administration. (1995) . Precautionary measures to further reduce the possible risk of transmission of Creutzfeldt-Jakob disease by blood and blood products. Memorandum from the Center for Biologics Evaluation and Research, Bethesda, MD, Aug 8, 1995. CBER
   Google Scholar
• Committee for Proprietary Medicinal Products. Note for guidance on plasma derived medicinal products. CPMPI BWP/269/95; 1996 Mar 13. European Agency for the Evaluation of Medicinal Products, London 1996
   Google Scholar
• Food and Drug Administration. (1996) . Revised precautionary measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products. Memorandum from the Center for Biologics Evaluation and Research, Bethesda, MD, Dec 11, 1996. CBER
   Google Scholar
• Committee for Proprietary Medicinal Products. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products. CPMP/BWP/877/96; 1997 Oct 22. European Agency for the Evaluation of Medicinal Products, London 1997
   Google Scholar
• UK Department of Health. Ministers accept SEAC advice on safety of blood products. Press Release 97/335; 1997 Nov. Department of Health, London 1997
   Google Scholar
• Council of Europe. Guide to the preparation, use and quality assurance of blood components. 4th edn. Council of Europe Publishing, StrasbourgFrance 1998
   Google Scholar
• Committee for Proprietary Medicinal Products. CPMP position statement on new variant CJD and plasma-derived medicinal products. Press Release CPMP/201/98; 1998 Feb 25. European Agency for the Evaluation of Medicinal Products, London 1998
   Google Scholar
• UK Department of Health. Further precautionary measures in blood products announced. Press Release 98/076; 1998 Feb 26. Department of Health, London 1998
   Google Scholar
• UK Department of Health. Committee on Safety of Medicines completes review of blood products. Press Release 98/282; 1998 May 13. Department of Health, London 1998
   Google Scholar
• UK Department of Health. Government accepts advice on leucodepletion from Spongiform Encephalopathy Advisory Committee. Press Release 98/295; 1998 July 17. Department of Health, London 1998
   Google Scholar
• Food and Drug Administration. Change to the guidance entitled Revised precautionary measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products. Memorandum from the Center for Biologics Evaluation and Research; 1998 Sep 8. CBER, Bethesda, MD 1998
   Google Scholar
• Council of Europe. Guide to the preparation, use and quality assurance of blood components. 5th edn. Council of Europe Publishing, StrasbourgFrance 1999
   Google Scholar
• Det Norske Veritas. Assessment of the risk of exposure to vCJD infectivity in blood and blood products: Final report for the Spongiform Encephalopathy Advisory Committee and the Department of Health. Det Norske Veritas, London 1999, http://www.dnv.com
   Google Scholar
• Committee for Proprietary Medicinal Products. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products. CPMB/BWP/1230/98; 1999 Apr 21. European Agency for the Evaluation of Medicinal Products, London 1999
   Google Scholar
• Food and Drug Administration. Revised precautionary measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nv CJD) by blood and blood products. Memorandum from the Center for Biologics Evaluation and Research; 1999 Aug. CBER, Bethesda, MD 1999
   Google Scholar
• Food and Drug Administration. Revised precautionary measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nv CJD) by blood and blood products. Memorandum from the Center for Biologics Evaluation and Research; 1999 Nov. CBER, Bethesda, MD 1999
   Google Scholar
• Kondo K, Kuroiwa Y. A case control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann Neurol 1982; 11: 377–81
   PubMedGoogle Scholar
• Davanipour Z, Alter M, Sobel E, Asher D M, Gajdusek DC. A case control study of Creutzfeldt-Jakob disease: dietary risk factors. Am J Epidemiol 1985; 122: 443–51
   Google Scholar
• Harries-Jones R, Knight R, Will R G, Cousens S, Smith P G, Matthews WB. Creutzfeldt-Jakob disease in England and Wales, 1980–1984: a case-control study of potential risk factors. J Neurol Neurosurg Psychiatry 1988; 51: 1113–9
   PubMedGoogle Scholar
• Will RG. Epidemiological surveillance of Creutzfeldt-Jakob disease in the United Kingdom. Eur J Epidemiol 1991; 7: 460–5
   Google Scholar
• Wientjens D P, Davanipour Z, Hofman A, Kondo K, Matthews W B, Will R G. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996; 46: 1287–91
   PubMedGoogle Scholar
• Van Duijn CM, Delasnerie-Laupretre Masullo C, Zerr I, De Silva R, Wientjens D P. Case control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993–95. European Union (EU) collaborative study group of Creutzfeldt-Jakob disease (CJD). Lancet 1998; 1081–5
   Google Scholar
• Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion. Curr Opin Hematol 1995; 2: 472–7
   Google Scholar
• Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, Jones R. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998; 38: 817–20
   Google Scholar
• Lee C A, Ironside J W, Bell J E, Giangrande P, Ludlam C, Esiri M M. Retrospective neuropathological review of prion disease in UK haemophilia patients. Thromb Haemost 1998; 80: 909–11
   Google Scholar
• Heye N, Hensen S, Muller N. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1994; 343: 298–9
   PubMed Web of Science ®Google Scholar
• Holman R C, Khan A S, Belay E D, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979–1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996; 2: 333–7
   Google Scholar
• Brown P. The risk of blood-borne Creutzfeldt-Jakob disease. Dev Biol Stand 2000; 102: 53–9
   Google Scholar
• Baron H, Safar J, Groth D, DeArmond S J, Prusiner SB. Biosafety issues in prion diseases. Prion biology and diseases, SB Prusiner. Cold Spring Harbor Laboratory Press, New York, NY 1999; 743–77
   Google Scholar
• Will R G, Alpers M P, Dormont D, Schonberger L B, Tateishi J. Infectious and sporadic prion diseases. Prion biology and diseases, SB Prusiner. Cold Spring Harbour Laboratory Press, New York, NY 1999; 465–507
   Google Scholar
• Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354: 317–23
   PubMed Web of Science ®Google Scholar
• Tyrrell D AJ, Taylor KC. Handling the BSE epidemic in Great Britain. Prion diseases, H Baker, RM Ridley. Humana Press, Totowa, NJ 1996; 175–98
   Google Scholar
• Bruce ME. ‘New variant’ Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Nat Med 2000; 6: 258–9
   Google Scholar
• Cousens S N, Vynnycky E, Zeidler M, Will R G, Smith PG. Predicting the CJD epidemic in humans. Nature 1997; 385: 197–8
   PubMed Web of Science ®Google Scholar
• Hill A F, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99–100
   PubMed Web of Science ®Google Scholar
• Ludlam CA. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet 1997; 350: 1740
   Google Scholar
• Warden J. UK blood products are banned. BMJ 1998; 316: 726
   Google Scholar
• Kuroda Y, Gibbs C J, Amyx H L, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983; 41: 154–61
   Google Scholar
• Dzik S, Aubuchon J, Jeffries L, Kleinman S, Manno C, Murphy M F. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000; 14: 34–52
   Google Scholar
• UK Creutzfeldt-Jakob Disease Surveillance Unit. CJD figures. CJD statistics; 2000 August 15. CJD Surveillance Unit, EdinburghUK, http://www.cjd.ed.ac.uk
   Google Scholar
• Oppenheim C, Brandel J P, Hauw J J, Deslys J P, Fontaine B. MRI and the second French case of vCJD. Lancet 2000; 356: 253–54
   Google Scholar
• Cohen C H, Valleron AJ. When did bovine spongiform encephalopathy (BSE) start? Implications on the prediction of a new variant of Creutzfeldt-Jakob disease (nv CJD) epidemic. Int J Epidemiol 1999; 28: 526–31
   Google Scholar
• Ghani A C, Donnelly C A, Ferguson N M, Anderson RM. Assessment of the prevalence of vCJD through testing tonsils and appendices for abnormal prion protein. Proc R Soc Lond B 2000; 267: 23–9
   Web of Science ®Google Scholar
• Ghani A C, Ferguson N M, Donnelly C, Anderson RM. Predicted vCJD mortality in Great Britain. Nature 2000; 406: 583–4
   PubMedGoogle Scholar
• Alper T, Cramp W A, Haig D A, Clarke MC. Does the agent of scrapie replicate without nucleic acid. Nature 1967; 214: 764–6
   PubMed Web of Science ®Google Scholar
• Alper T, Haig D A, Clarke MC. The scrapie agent: evidence against its dependence for replication on intrinsic nucleic acid. J Gen Virol 1978; 41: 503–16
   PubMedGoogle Scholar
• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136–44
   PubMed Web of Science ®Google Scholar
• Griffith JS. Self-replication and scrapie. Nature 1967; 215: 1043–4
   PubMed Web of Science ®Google Scholar
• Oesch B, Westaway D, Walchlo M, McKinley M P, Kent S BH, Aebersold R. A cellular gene encodes scrapie PrP27–30 protein. Cell 1985; 40: 735–46
   PubMed Web of Science ®Google Scholar
• Pan K M, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993; 90: 10962–6
   PubMed Web of Science ®Google Scholar
• Cohen F E, Prusiner SB. Pathological conformations of prion proteins. Annu Rev Biochem 1998; 67: 793–819
   PubMed Web of Science ®Google Scholar
• Rubenstein R, Kascsak R J, Merz P A, Papini M C, Carp R I, Robakis N K. Detection of scrapie-associated fibril (SAF) proteins using anti-SAF antibody in non-purified tissue preparations. J Gen Virol 1986; 67: 671–81
   PubMedGoogle Scholar
• Kascsak R J, Tonna-DeMasi M, Fersko R, Rubenstein R, Carp R I, Powers JM. The role of antibodies to PrP in the diagnosis of transmissible spongiform encephalopathies. Dev Biol Stand 1993; 80: 141–51
   Google Scholar
• McKinley M P, Meyer R K, Kenaga L, Rahbar F, Cotter R, Serban A. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J Virol 1999; 65: 1340–51
   Google Scholar
• Gasset M, Baldwin M A, Fletterick R J, Prusiner RB. Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. Proc Natl Acad Sci USA 1993; 90: 1–5
   PubMed Web of Science ®Google Scholar
• Prusiner S B, Groth D F, Cochran S P, Masiarz F R, McKinley M P, Martinez HM. Molecular properties partial purification, and assay by incubation period measurements of the hamster scrapie agent. Biochemistry 1980; 19: 4883–91
   PubMedGoogle Scholar
• Turk E, Teplow D B, Hood L E, Prusiner SB. Purification and properties of the cellular and scrapie hamster prion proteins. Eur J Biochem 1988; 176: 21–30
   PubMedGoogle Scholar
• Meyer R K, McKinley M P, Bowman K A, Braunfeld M B, Barry R A, Prusiner SB. Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci USA 1986; 83: 2310–14
   PubMed Web of Science ®Google Scholar
• Bolton D C, Bendheim P E, Marmorstein A D, Potomska A. Isolation and structural studies of the intact scrapie agent protein. Arch Biochem Biophys 1987; 258: 579–90
   PubMed Web of Science ®Google Scholar
• Stahl N, Borchelt D R, Prusiner SB. Differential release of cellular and scrapie prion proteins from cellular membranes by phosphatidylinositol-specific phospholipase C. Biochemistry 1990; 29: 5405–12
   PubMed Web of Science ®Google Scholar
• Bader F, Davis G, Dinowitz M, Garfinkle B, Harvey J, Kozak R. Assessment of risk of bovine spongiform encephalopathy in pharmaceutical products, part 1. Biopharmacology 1998; 11: 20–31; 56
   Google Scholar
• Tateishi J. Transmission of Creutzfeldt-Jakob disease from human blood and urine into mice. Lancet 1985; ii: 1074
   Google Scholar
• Manuelidis E E, Kim J H, Mericangas J R, Manuelidis L. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet 1985; ii: 896–7
   Google Scholar
• Deslys J P, Lasmézas C, Dormont D. Selection of specific strains in iatrogenic Creutzfeldt-Jakob disease. Lancet 1994; 343: 848–9
   PubMed Web of Science ®Google Scholar
• Tamai Y, Kojima H, Kitajima R, Taguchi F, Ohtani Y, Kawaguchi T. Demonstration of the transmissible agent in tissue from a pregnant woman with Creutzfeldt-Jakob disease. N Engl J Med 1992; 327: 649
   PubMed Web of Science ®Google Scholar
• Brown P, Cervenáková L, Goldfarb L G, McCombie W R, Rubenstein R, Will R G. Iatrogenic Creutzfeldt-Jakob disease: an example of the interplay between ancient genes and modern medicine. Neurology 1994; 44: 291–3
   PubMedGoogle Scholar
• Kimberlin R H, Walker CA. Pathogenesis of scrapie: agent multiplication in brain at the first and second passage of hamster scrapie in mice. J Gen Virol 1979; 42: 107–17
   PubMedGoogle Scholar
• Rohwer RG. Experimental studies of blood infected with TSE agents. Proceedings of the Fourth Meeting of the FDA Advisory Committee on Transmissible Spongiform Encephalopathies, Bethesda, MD, Dec 18, 1998, Fairfax Caset 1999. http://www.fda.gov/ohrms/dockets
   Google Scholar
• Diringer H. Sustained viremia in experimental hamster scrapie. Arch Virol 1984; 82: 105–9
   Google Scholar
• Casaccia P, Ladogana A, Xi Y G, Pocchiari M. Levels of infectivity in the blood throughout the incubation period of hamsters peripherally infected with scrapie. Arch Virol 1989; 108: 145–9
   Google Scholar
• Brown P, Rohwer R G, Dunstan B C, MacAuley C, Gajdusek D C, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810–6
   PubMed Web of Science ®Google Scholar
• Bradley R. BSE transmission studies with particular reference to blood. Dev Biol Stand 1999; 99: 35–40
   PubMedGoogle Scholar
• Kimberlin RH. Bovine spongiform encephalopathy and public health: some problems and solutions in assessing the risks. Transmissible subacute spongiform encephalopathies: prion diseases, L Court, B Dodet. Elsevier, ParisFrance 1996; 487–502
   Google Scholar
• Taylor D M, Fernie K, Reichl H E, Somerville RA. Infectivity in the blood of mice with a BSE-derived agent. J Hosp Infect, (in press)
   Google Scholar
• Mollison P L, Englefriet C P, Contreras M, Jones J. Blood transfusion in clinical medicine. 10th edn. Blackwell Science, OxfordUK 1997
   Google Scholar
• McClelland B. Handbook of transfusion medicine. 2nd ed. Her Majesty's Stationery Office, London 1996
   Google Scholar
• Tomasulo P. Transfusion alternatives: impact on blood banking world-wide. Blood substitutes: physiological basis of efficacy, R Winslow, K Vandegriff, M Intaglietta. Birkirkhauser, Cambridge 1995; 1–19
   Google Scholar
• Marketing Research Bureau. International directory of plasma fractionators 1999. Marketing Research Bureau, Orange, CT 2000
   Google Scholar
• Dzik S. Leukodepletion blood filters: filter design and mechanisms of leucocyte removal. Transfus Med Rev 1993; 65–77
   Google Scholar
• Foster PR. Blood plasma fractionation. Kirk-Othmer encyclopedia of chemical technology, 4th ed, M Howe-Grant. Wiley, New York, NY 1994; 990–1021
   Google Scholar
• Cuthbertson B, Reid K G, Foster PR. Viral contamination of human plasma and procedures for preventing virus transmission by plasma products. Blood separation and plasma fractionation, JR Harris. Wiley-Liss, New York, NY 1991; 385–435
   Google Scholar
• Brown P, Cervenáková L, McShane L M, Barber P, Rubenstein R, Drohan WN. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169–78
   PubMed Web of Science ®Google Scholar
• Rohwer RG. (2000) Experimental studies with blood infected with rodent-adapted scrapie and CJD agents. Proceedings of the FDA Transmissible Spongiform Encephalopathies Advisory Committee, Gaithersburg, MD, June 2, 2000. SAG Corp, http://www.fda.gov/ohrms/dockets
   Google Scholar
• Rohwer RG. (2000) Titre, distribution and transmissibility of blood-borne TSE infectivity. Presented at the 2nd IBC Annual Conference on Biological Safety and Production. June 20–23, 2000. International Business Communications, Washington, DC
   Google Scholar
• Taylor DM. Inactivation of prions by physical and chemical means. J Hosp Infect 1999; 43: S69–76, Suppl
   PubMed Web of Science ®Google Scholar
• Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999; 9: 3–14
   Google Scholar
• Lee D, Stenland C, Gilligan K, Ford E, Hartwell R, Cai K. PrPSC partitioning during plasma fractionation. Development and application of a sensitive Western blot assay. Thromb Haemost 1999; 82: 757, (Suppl)
   Google Scholar
• Lee D C, Stenland C J, Hartwell R C, Ford E K, Cai K, Miller J LC. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of prion protein. J Virol Methods 2000; 84: 77–89
   PubMed Web of Science ®Google Scholar
• Morgenthaler JJ. (1998) Partitioning of TSE agentjs) during ethanol fractionation of human plasma. Proceedings of Cambridge Healthtech Institute Conference ‘TSE issues’, LisbonPortugal, Nov 18, 1998. Cambridge Healthtech Institute, Newton Upper Falls, MA
   Google Scholar
• Drohan WN. (1999) Removal of scrapie infectivity during the purification of factor VIII. Proceedings of Cambridge Healthtech Institute's Fifth Annual Conference ‘Blood Safety and Screening’, McLean, VAUSA, Feb 22–24, 1999. Cambridge Healthtech Institute, Newton Upper Falls, MA
   Google Scholar
• Foster P R, Welch A G, McLean C, Griffin B D, Hardy J C, Bartley A. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78: 86–95
   PubMed Web of Science ®Google Scholar
• Cohn E J, Strong L E, Hughes W L, Mulford D J, Ashworth J N, Taylor HL. Preparation and properties of serum and plasma proteins. iv. A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68: 459–75
   PubMed Web of Science ®Google Scholar
• Oncley J L, Melin M, Richert D A, Cameron J W, Gross PM. The separation of the antibodies isoagglutinins, prothrombin, plasminogen, and beta,-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949; 71: 541–50
   PubMed Web of Science ®Google Scholar
• Kistler P, Nitschmann H. Large-scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962; 7: 414–24
   PubMed Web of Science ®Google Scholar
• Hink J H, Hidalgo J, Seeberg V P, Johnson FF. Preparation and properties of a heat-treated human plasma protein fraction. Vox Sang 1957; 2: 174–86
   Google Scholar
• Vogelaar E F, Boer-v d Berg M AG, Brummelhuis H GJ, Beentjes S P, Krijnen HW. Contributions to the optimal use of human blood iv. Quantitative analysis of the immunoglobulin isolation. Vox Sang 1974; 27: 193–206
   Google Scholar
• Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M. Eight prion strains have PrPSc molecules with different conformations. Nut Med 1998; 4: 1157–65
   PubMed Web of Science ®Google Scholar
• MacGregor I. Prion protein and developments in its detection. Transfus Med, (in press)
   Google Scholar
• Mould D L, Dawson A M, Smith W. Determination of the dosage-response curve of mice inoculated with scrapie. J Comp Pathol 1967; 77: 387–91
   Google Scholar
• Taylor D M, Woodgate S L, Atkinson MJ. Inactivation of the bovine spongiform encephalopathy agent by rendering procedures. Vet Rec 1995; 137: 605–10
   PubMed Web of Science ®Google Scholar
• McLean C, Harbour. C. Contamination detection in animal cell culture. Encyclopaedia of cell technology, RE Spier, B Griffin, AH Scragg. Wiley, New York, NY 2000; 586–609
   Google Scholar
• Aguzzi A. Prion diseases, blood and the immune system: concerns and reality. Haematologica 2000; 85: 3–10
   PubMedGoogle Scholar
• Diringer H, Roehmel J, Beekes M. Effect of repeated oral infection of hamsters with scrapie. J Gen Virol 1998; 79: 609–12
   PubMed Web of Science ®Google Scholar
• Kimberlin R H, Walker CA. Pathogenesis of scrapie in mice after intragastric infection. Virus Res 1989; 12: 213–20
   PubMed Web of Science ®Google Scholar
• Hill A F, Butterworth R J, Joiner S, Jackson G, Rossor M N, Thomas D J. Investigation of variant Creutzfeldt-Jakob disease and other human prion disease with tonsil biopsy samples. Lancet 1999; 353: 183–9
   PubMed Web of Science ®Google Scholar
• Houston F, Foster J D, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999–1000
   PubMed Web of Science ®Google Scholar